Physician profile
Darin Michael Olde
NPI 1699054478
$8,719.28
in general payments reported to CMS, 2019-2025
53 companies · $1,840 in 2025
The $1,840 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $929 · 2023: $3,498 · 2024: $2,453 · 2025: $1,840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,206 · Consulting Fee: $2,313 · Education: $272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,205.96 |
| Consulting Fee | $2,312.50 |
| Education | $271.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $2,496.92 | 2022-2025 | Enhertu, Injectafer, Datroway |
| E.R. Squibb & Sons, L.L.C. | $476.81 | 2022-2025 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $445.48 | 2022-2025 | Imfinzi, Enhertu, Lynparza |
| Janssen Biotech, INC. | $374.24 | 2023-2025 | Rybrevant, Carvykti, Balversa |
| Genzyme Corporation | $332.91 | 2022-2025 | |
| Astellas Pharma US INC | $315.36 | 2022-2025 | Padcev, Xtandi, Xospata |
| Merck Sharp & Dohme LLC | $293.65 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Incyte Corporation | $275.16 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
| Novartis Pharmaceuticals Corporation | $227.91 | 2022-2025 | |
| Pfizer INC. | $217.07 | 2023-2025 | |
| Springworks Therapeutics, INC. | $200.04 | 2024-2025 | Ogsiveo |
| Ipsen Biopharmaceuticals, INC | $186.20 | 2022-2025 | Onivyde |
| Spectrum Pharmaceuticals INC. | $181.85 | 2023 | Rolvedon |
| Amgen INC. | $175.11 | 2022-2023 | Kyprolis, Blincyto, Xgeva |
| Glaxosmithkline, LLC. | $158.22 | 2022-2025 | Ojjaara, Blenrep |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $147.45 | 2023-2025 | Phesgo, Perjeta, Itovebi |
| Eisai INC. | $141.31 | 2023-2025 | |
| Gilead Sciences, INC. | $135.21 | 2023-2025 | Trodelvy |
| Kite Pharma, INC. | $128.43 | 2023 | Yescarta |
| Sobi, INC | $126.60 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $123.11 | 2023-2025 | Ninlaro, Iclusig, Fruzaqla |
| Regeneron Healthcare Solutions, INC. | $107.32 | 2023-2025 | Libtayo |
| Blueprint Medicines Corporation | $106.95 | 2022 | |
| Deciphera Pharmaceuticals INC. | $102.50 | 2023-2025 | Qinlock, Romvimza |
| Servier Pharmaceuticals LLC | $80.52 | 2023-2025 | |
| Kyowa Kirin, INC. | $78.53 | 2022-2025 | Poteligeo |
| Acrotech Biopharma INC. | $77.85 | 2023-2025 | Beleodaq |
| Seagen INC. | $76.54 | 2023 | Padcev, Tukysa, Adcetris |
| Jazz Pharmaceuticals INC. | $70.28 | 2023-2025 | |
| Abbvie INC. | $66.33 | 2023-2024 | |
| Tersera Therapeutics LLC | $57.96 | 2023-2025 | Zoladex |
| Octapharma USA, INC. | $53.41 | 2023-2024 | Panzyga, Octagam Immune Globulin (Human) |
| Mirati Therapeutics, INC. | $49.99 | 2024 | Krazati |
| Array Biopharma INC | $49.96 | 2024 | Mektovi, Braftovi, Tukysa |
| Lilly USA, LLC | $46.29 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Apellis Pharmaceuticals, INC. | $45.75 | 2022-2023 | Empaveli |
| Alexion Pharmaceuticals, INC. | $45.68 | 2024-2025 | Ultomiris |
| Emd Serono, INC. | $44.38 | 2023-2024 | Bavencio |
| Celgene Corporation | $43.99 | 2022-2023 | Reblozyl |
| Organon LLC | $41.79 | 2022-2023 | Ontruzant |
| Exelixis INC. | $32.47 | 2025 | Cabometyx |
| Stemline Therapeutics INC. | $30.94 | 2023 | Orserdu |
| Syndax Pharmaceuticals, INC. | $28.28 | 2025 | |
| Aveo Pharmaceuticals, INC. | $28.18 | 2022 | |
| Verity Pharmaceuticals INC. | $28.15 | 2024 | Trelstar |
| Pharmaessentia USA Corporation | $27.77 | 2023 | Besremi |
| Genmab U.S., INC. | $26.16 | 2025 | Epkinly |
| Adc Therapeutics America, INC. | $24.75 | 2024 | |
| Morphosys, US INC. | $22.28 | 2023 | Monjuvi |
| Agios Pharmaceuticals, INC. | $21.71 | 2025 | Pyrukynd |
| Bayer Healthcare Pharmaceuticals INC. | $16.27 | 2023 | |
| Menarini Silicon Biosystems, INC. | $13.68 | 2025 | |
| Eusa Pharma (US) LLC | $13.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darin Olde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.